vorinostat has been researched along with Dehydration in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Dehydration: The condition that results from excessive loss of water from a living organism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 9.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)." | 5.12 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duvic, M | 1 |
| Talpur, R | 1 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Hazarika, P | 1 |
| Kelly, C | 1 |
| Chiao, JH | 1 |
| Reilly, JF | 1 |
| Ricker, JL | 1 |
| Richon, VM | 1 |
| Frankel, SR | 1 |
1 trial available for vorinostat and Dehydration
| Article | Year |
|---|---|
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre | 2007 |